REG - Oxford Biomedica PLC - Result of AGM
RNS Number : 1127AOxford Biomedica PLC28 May 2021
Oxford Biomedica
Result of Annual General Meeting
Oxford, UK - 28 May 2021: Oxford Biomedica plc (LSE:OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held at 3pm on 27 May 2021 in Oxford. As proposed in the Notice of AGM, all resolutions were decided by poll vote.
The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxb.com
Copies of the document setting out the above resolutions passed at the 2021 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
On the Record Date (25 May 2021) there were 82,543,197 ordinary shares of 50 pence each in issue, each carrying one vote per share.
Resolution
Votes
For
Votes at
Chairman's
Discretion
Votes at
other proxy
Discretion
Votes
Against
Votes
Withheld*
Total
votes cast
Result
Ordinary resolutions
1
To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2020
58,334,279 (99.99%)
8,574 (0.01%)
0
1,440 (0.00%)
59,353
58,344,293
Passed
2
To receive the Directors' Remuneration Report and the Report of the Auditor on the Remuneration Report for the year ended 31 December 2020
57,033,865 (98.72%)
8,574 (0.01%)
0
731,131 (1.27%)
630,076
57,773,570
Passed
3
To approve the Directors' Remuneration Policy
46,429,406 (80.94%)
8,574 (0.01%)
0
10,926,461 (19.05%)
1,039,205
57,364,441
Passed
4
To appoint Dr. Roch Doliveux as a Director.
57,832,864 (99.04%)
8,574 (0.01%)
0
554,706 (0.95%)
7,502
58,396,144
Passed
5
To appoint Professor Dame Kay Davies as a Director
58,385,668 (99.99)
8,574 (0.01%)
0
1,640 (0.00%)
7,764
58,395,882
Passed
6
To appoint Dr. Siyamak Rasty as a Director
58,325,223 (99.88%)
8,574 (0.01%)
0
62,347 (0.11%)
7,502
58,396,144
Passed
7
To reappoint John Dawson as a Director
58,194,899 (99.66%)
8,574 (0.01%)
0
192,871 (0.33%)
7,302
58,396,344
Passed
8
To reappoint Stuart Paynter as a Director
58,195,041 (99.66%)
8,574 (0.01%)
0
192,729 (0.33%)
7,302
58,396,344
Passed
9
To reappoint Stuart Henderson as a Director
55,957,927 (95.84%)
8,574 (0.01%)
0
2,423,167 (4.15%)
13,978
58,389,668
Passed
10
To reappoint Dr. Heather Preston as a Director
55,966,994 (95.84%)
8,574 (0.01%)
0
2,421,352 (4.15%)
6,726
58,396,920
Passed
11
To reappoint Robert Ghenchev as a Director
58,193,434 (99.66%)
8,574 (0.01%)
0
194,336 (0.33%)
7,302
58,396,344
Passed
12
To reappoint KMPG LLP as auditor
58,376,747 (99.98%)
8,674 (0.01%)
0
6,633 (0.01%)
11,592
58,392,054
Passed
13
To authorise the Directors to agree the remuneration of the auditor
57,756,307 (99.98%)
8,574 (0.01%)
0
5,556 (0.01%)
633,209
57,770,437
Passed
14
To amend the rules of the Oxford Biomedica 2015
Long Term Incentive Plan
46,776,691 (81.55%)
8,574 (0.01%)
0
10,579,473 (18.44%)
1,038,908
57,364,738
Passed
15
To amend the rules of the Oxford Biomedica 2015
Executive Share Option Scheme
46,773,232 (81.54%)
8,574 (0.01%)
0
10,582,625 (18.45%)
10,582,625 (18.45%)
57,364,431
Passed
16
To authorise the Directors to allot shares
55,826,926 (96.64%)
8,574 (0.01%)
0
1,936,496 (3.35%)
631,650
57,771,996
Passed
Special resolutions
17
To authorise the Directors to disapplypre-emption rights
57,477,832 (99.49%)
8,574 (0.01%)
0
286,354 (0.50%)
630,886
57,772,760
Passed
18
To authorise the Directors to further disapply pre-emption rights foracquisitions and specified capital investments
57,477,350 (99.49%)
8,574 (0.01%)
0
286,636 (0.50%)
631,086
57,772,560
Passed
19
To permit the Directors to convene general meetings (other than annual general meetings) on not less than 14 days' notice
56,393,012 (96.57%)
8,574 (0.01%)
0
1,996,782 (3.42%)
5,278
58,398,368
Passed
* A vote withheld is not a vote in law and is not counted towards votes cast in respect of a resolution.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
T: +44 (0)1865 783 000
T: +44 (0)1865 783 000
T: +44 (0)1865 954 161 / E: ir@oxb.com
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDRAGSEDESWEFSELI
Recent news on Oxford BioMedica
See all newsREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - 2023 Annual Report and Accounts
AnnouncementREG - Oxford Biomedica PLC - Total Voting Rights
AnnouncementREG - Oxford Biomedica PLC - Update on CDMO Services
AnnouncementREG - Oxford Biomedica PLC - Board Changes
Announcement